Characteristics of patients in the study
| . | Athens (n = 107) . | Pavia (n = 202) . | P . |
|---|---|---|---|
| Male/female | 59%/41% | 54%/46% | .442 |
| Median age, years | 67 | 65 | .597 |
| dFLC >180 mg/L | 52% | 48.5% | .567 |
| Heart involvement | 62% | 77% | .007 |
| Mayo stage 1/2/3A/3B | 26%/43%/11%/15% | 15%/43%/27%/15% | .041 |
| Renal involvement | 72% | 67% | .415 |
| Median eGFR, mL/min per 1.73 m2 | 61 | 62 | .807 |
| eGFR <50 ml/min per 1.73 m2 | 34% | 36% | .545 |
| Median proteinuria, g/d | 6.5 | 5.1 | .544 |
| Proteinuria >5 g/d* | 61% | 56% | .178 |
| Renal stage 1/2/3† | 20%/54%/26% | 26%/54%/20% | .528 |
| Liver involvement | 17% | 12% | .284 |
| Nerve involvement | 25% | 11% | .001 |
| Primary therapy | <.001 | ||
| Bortezomib | 60% | 86% | |
| Lenalidomide | 33% | 0 | |
| MDex | 7% | 11% | |
| High-dose therapy with ASCT during disease course | 5% | 7% | .605 |
| CR + VGPR as response to primary therapy | 42% | 45% | .599 |
| . | Athens (n = 107) . | Pavia (n = 202) . | P . |
|---|---|---|---|
| Male/female | 59%/41% | 54%/46% | .442 |
| Median age, years | 67 | 65 | .597 |
| dFLC >180 mg/L | 52% | 48.5% | .567 |
| Heart involvement | 62% | 77% | .007 |
| Mayo stage 1/2/3A/3B | 26%/43%/11%/15% | 15%/43%/27%/15% | .041 |
| Renal involvement | 72% | 67% | .415 |
| Median eGFR, mL/min per 1.73 m2 | 61 | 62 | .807 |
| eGFR <50 ml/min per 1.73 m2 | 34% | 36% | .545 |
| Median proteinuria, g/d | 6.5 | 5.1 | .544 |
| Proteinuria >5 g/d* | 61% | 56% | .178 |
| Renal stage 1/2/3† | 20%/54%/26% | 26%/54%/20% | .528 |
| Liver involvement | 17% | 12% | .284 |
| Nerve involvement | 25% | 11% | .001 |
| Primary therapy | <.001 | ||
| Bortezomib | 60% | 86% | |
| Lenalidomide | 33% | 0 | |
| MDex | 7% | 11% | |
| High-dose therapy with ASCT during disease course | 5% | 7% | .605 |
| CR + VGPR as response to primary therapy | 42% | 45% | .599 |
ASCT, autologous stem-cell transplantation; CR, complete response; dFLC, difference between involved and uninvolved free light chains; eGFR, estimated glomerular filtration rate; MDex, melphalan plus dexamethasone; VGPR, very good PR.